321 related articles for article (PubMed ID: 30231561)
1. Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.
Poggio T; Duyster J; Illert AL
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30231561
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
4. Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Pytlik R; Polgarova K; Karolova J; Klener P
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33260966
[TBL] [Abstract][Full Text] [Related]
5. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
Van-de-Velde V; Zhou Y
J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
[TBL] [Abstract][Full Text] [Related]
6. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
7. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
10. Current targeted therapies in lymphomas.
Chung C
Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
12. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.
Sheikh IN; Elgehiny A; Ragoonanan D; Mahadeo KM; Nieto Y; Khazal S
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740580
[TBL] [Abstract][Full Text] [Related]
13. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
Kyriakidis I; Vasileiou E; Rossig C; Roilides E; Groll AH; Tragiannidis A
J Fungi (Basel); 2021 Mar; 7(3):. PubMed ID: 33807678
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma Immunotherapy: Current Status.
Zappasodi R; de Braud F; Di Nicola M
Front Immunol; 2015; 6():448. PubMed ID: 26388871
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
Pierce JM; Mehta A
Expert Rev Hematol; 2017 Jan; 10(1):29-37. PubMed ID: 27927047
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with drugs.
Choi Y; Diefenbach CS
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):598-605. PubMed ID: 33275686
[TBL] [Abstract][Full Text] [Related]
20. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aujla A; Aujla R; Liu D
Biomark Res; 2019; 7():9. PubMed ID: 31011424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
